In this illustrated picture taken on March 19, 2021, you can see the vials with Pfizer BioNTech and Moderna coronavirus disease (COVID-19) vaccine labels.
Given Luvić | Reuters
Moderna defended its use of the Covid-19 vaccine on Thursday, saying that the protection it provides against serious illness, hospitalization and death exceeds the risk of myocarditis, a rare type of heart disease seen in a small number of young men who have been vaccinated.
The company announced last week that the Food and Drug Administration needs more time to decide whether to authorize its two-dose vaccine for children aged 12 to 17 because the agency is investigating reports of myocarditis or inflammation of the heart muscle.
Moderna Chief Medical Officer Paul Burton told reporters on a conference call on Thursday that compared with patients receiving Pfizer and BioNTech vaccines, the incidence of rare reported cases of heart inflammation in men under 30 years old is relatively higher after being vaccinated with Moderna vaccine.
Burton cited data from French men aged 12 to 29. The data shows that Moderna’s vaccine has 13.3 cases of myocarditis per 100,000 people, while Pfizer’s vaccine has 2.7 cases per 100,000 people.
However, he also touted data from the Centers for Disease Control and Prevention, which showed that the incidence of Covid mild or severe disease among Moderna recipients was lower than those receiving Pfizer or Johnson & Johnson vaccines.
He said on the phone: “Although I think the health authorities are carefully evaluating the data, with due caution, you can see that they continue to recommend the use of the mRNA-1273 Moderna vaccine.” “We believe that the balance of benefits and risks is very positive,” He added.
This is a story of development. Please check for updates.
If you want to know more about business please go to https://updatednews24.com/category/business/